Literature DB >> 23961264

Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas.

Adam Deising1, Ramiro L Gutierrez, Chad K Porter, Mark S Riddle.   

Abstract

Epidemiologic research is fundamental and complementary to our understanding of disease and development of primary, secondary, and tertiary interventions. To put the current evidence into context and identify gaps and research priorities in the areas of disease attribution, burden of disease, clinical characterization, and management of postinfectious functional gastrointestinal disorders (PI-FGDs), we took a multidisciplinary approach from the domains of infectious disease, gastroenterology, epidemiology, and public health. Our review of data from these disciplines found that, despite a complete understanding of pathoetiology, studies continue to accumulate and point toward evidence of a causal association for FGD. For some FGDs, Bradford Hill's criteria for causality yield more certainty than other criteria. In addition, the growing recognition of the impact of acute foodborne illness on economics and society is leading to exploration of the potential long-term health effects and disease burden of PI-FGDs, although a paucity of data exist in terms of pathogen-specific risk, disability duration, and relevant disability weights. Lastly, the understanding of PI-FGDs is changing the way research is approached and suggests a need for a more expansive exploration of biologic mechanisms and how FGDs are categorized. Areas of research priorities are catalogued in this paper and will hopefully provide inspiration for future studies and contributions to the field of gastroenterology.

Entities:  

Keywords:  Functional gastrointestinal disorder; causation; dyspepsia; irritable bowel syndrome; qualitative review

Year:  2013        PMID: 23961264      PMCID: PMC3745203     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  116 in total

Review 1.  Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases.

Authors:  James E Everhart; Constance E Ruhl
Journal:  Gastroenterology       Date:  2009-01-03       Impact factor: 22.682

Review 2.  Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets.

Authors:  G Dahlqvist; H Piessevaux
Journal:  Acta Gastroenterol Belg       Date:  2011-09       Impact factor: 1.316

3.  Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese outpatient office and the impact of overlapping.

Authors:  Shigemi Nakajima; Keiko Takahashi; Jin Sato; Masako Fukuda; Kazuo Yamamoto; Tetsuya Inoue; Yoshiaki Okumura; Yoshihide Fujiyama
Journal:  J Gastroenterol Hepatol       Date:  2010-05       Impact factor: 4.029

Review 4.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

Review 5.  [Post-infectious irritable bowel syndrome].

Authors:  F Pallotti; E Fogacci; C Frisoni; M Serra; L Bellacosa; G Carini; C Cremon; R De Giorgio; V Stanghellini; R Corinaldesi; G Barbara
Journal:  Clin Ter       Date:  2011

Review 6.  Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome.

Authors:  Hong-Yan Qin; Justin C Y Wu; Xu-Dong Tong; Joseph J Y Sung; Hong-Xi Xu; Zhao-Xiang Bian
Journal:  J Gastroenterol       Date:  2010-09-17       Impact factor: 7.527

7.  Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

Authors:  K R Neal; L Barker; R C Spiller
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

8.  The clinical course of postinfectious irritable bowel syndrome: a five-year follow-up study.

Authors:  In Su Jung; Hee Sun Kim; Hyojin Park; Sang In Lee
Journal:  J Clin Gastroenterol       Date:  2009-07       Impact factor: 3.062

9.  The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors.

Authors:  Kwang Jae Lee; Yeong Bae Kim; Jang Hee Kim; Hoek Chun Kwon; Dong Kyu Kim; Sung Won Cho
Journal:  J Gastroenterol Hepatol       Date:  2008-11       Impact factor: 4.029

10.  Infectious gastroenteritis and risk of developing inflammatory bowel disease.

Authors:  Chad K Porter; David R Tribble; Pablo A Aliaga; Heather A Halvorson; Mark S Riddle
Journal:  Gastroenterology       Date:  2008-06-05       Impact factor: 22.682

View more
  5 in total

Review 1.  The Traveling Microbiome.

Authors:  Mark S Riddle; Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

2.  The Epidemiology of Irritable Bowel Syndrome in the US Military: Findings from the Millennium Cohort Study.

Authors:  Mark S Riddle; Marleen Welsh; Chad K Porter; Chiping Nieh; Edward J Boyko; Gary Gackstetter; Tomoko I Hooper
Journal:  Am J Gastroenterol       Date:  2016-01-05       Impact factor: 10.864

3.  Common Gastrointestinal Symptoms and Associated Factors Among Under-5 Children in Rural Dembiya, Northwest Ethiopia: A Community-Based Cross-Sectional Study.

Authors:  Zemichael Gizaw; Ayenew Addisu; Destaye Guadie
Journal:  Environ Health Insights       Date:  2020-06-17

4.  Estimating the incidence of norovirus acute gastroenteritis among US and European international travelers to areas of moderate to high risk of traveler's diarrhea: a prospective cohort study protocol.

Authors:  Lisa Lindsay; Herbert L DuPont; Christine L Moe; Martin Alberer; Christoph Hatz; Amy E Kirby; Henry M Wu; Thomas Verstraeten; Robert Steffen
Journal:  BMC Infect Dis       Date:  2018-12-03       Impact factor: 3.090

5.  The Risk of Chronic Gastrointestinal Disorders Following Acute Infection with Intestinal Parasites.

Authors:  Jason Blitz; Mark S Riddle; Chad K Porter
Journal:  Front Microbiol       Date:  2018-01-23       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.